PDF
Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021
Organization: United States Centers for Disease Control (CDC)Published: 2021
"On August 23, 2021, the Food and Drug Administration granted full approval of the Pfizer-BioNTech COVID-19 vaccine for persons aged ≥16 years. On August 30, 2021, after a systematic review of the data, the Advisory Committee on Immunization Practices revised its interim recommendation to a standard recommendation for use of the Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years for the prevention of COVID-19. Continued use of the Pfizer-BioNTech COVID-19 vaccine, now fully approved by the FDA in persons aged ≥16 years, is recommended based on increased certainty that its benefits (prevention of asymptomatic infection, COVID-19, and associated hospitalization and death) outweigh vaccine-associated risks." - United States Centers for Disease Control and Prevention
Additional Authors: Amy E. Blain, Stephen C. Hadler, Ian D. Plumb, Heidi Moline, Jack Gerstein, Jennifer P. Collins, Monica Godfrey, Doug Campos-Outcalt, Rebecca L. Morgan, Oliver Brooks, H. Keipp Talbot, Grace M. Lee, Matthew F. Daley, Sara E. Oliver
Product Type: Report
Category:
Vaccine Safety and Development,Research and Development,Vaccine Effectiveness and Efficacy,Vaccine Safety,Sub Topics: Vaccine Safety and Development,Adverse Events Following Immunization (AEFI),Monitoring and Surveillance,Outbreaks and Pandemics,COVID-19 Vaccine Safety and DevelopmentResearch and Development
Vaccine Effectiveness and Efficacy
Vaccine Safety
Sub Topics: Vaccine Safety and Development
Adverse Events Following Immunization (AEFI)
Monitoring and Surveillance
Outbreaks and Pandemics
COVID-19
Link
AudioResource Rating Breakdown
Ratings submitted by CANVax users for this resource are tallied to provide an average resource rating per category.
0 Comments
Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.
All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.
You must login or register before you can submit a comment.